<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35460319</PMID><DateCompleted><Year>2022</Year><Month>07</Month><Day>18</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1468-1331</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>8</Issue><PubDate><Year>2022</Year><Month>Aug</Month></PubDate></JournalIssue><Title>European journal of neurology</Title><ISOAbbreviation>Eur J Neurol</ISOAbbreviation></Journal><ArticleTitle>COVID-19 vaccination hesitancy among people with chronic neurological disorders: A position paper.</ArticleTitle><Pagination><StartPage>2163</StartPage><EndPage>2172</EndPage><MedlinePgn>2163-2172</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/ene.15368</ELocationID><Abstract><AbstractText Label="BACKGROUND AND PURPOSE">Health risks associated with SARS-CoV-2 infection are undisputed. Moreover, the capability of vaccination to prevent symptomatic, severe, and fatal COVID-19 is recognized. There is also early evidence that vaccination can reduce the chance for long COVID-19. Nonetheless, the willingness to get vaccinated and receive booster shots remains subpar among people with neurologic disorders. Vaccine scepticism not only jeopardizes collective efforts to end the COVID-19 pandemic but puts individual lives at risk, as some chronic neurologic diseases are associated with a higher risk for an unfavorable COVID-19 course.</AbstractText><AbstractText Label="METHODS">In this position paper, the NeuroCOVID-19 Task Force of the European Academy of Neurology (EAN) summarizes the current knowledge on the prognosis of COVID-19 among patients with neurologic disease, elucidates potential barriers to vaccination coverage, and formulates strategies to overcome vaccination hesitancy. A survey among the Task Force members on the phenomenon of vaccination hesitancy among people with neurologic disease supports the lines of argumentation.</AbstractText><AbstractText Label="RESULTS">The study revealed that people with multiple sclerosis and other nervous system autoimmune disorders are most skeptical of SARS-CoV-2 vaccination. The prevailing concerns included the chance of worsening the pre-existing neurological condition, vaccination-related adverse events, and drug interaction.</AbstractText><AbstractText Label="CONCLUSIONS">The EAN NeuroCOVID-19 Task Force reinforces the key role of neurologists as advocates of COVID-19 vaccination. Neurologists need to argue in the interest of their patients about the overwhelming individual and global benefits of COVID-19 vaccination. Moreover, they need to keep on eye on this vulnerable patient group, its concerns, and the emergence of potential safety signals.</AbstractText><CopyrightInformation>&#xa9; 2022 The Authors. European Journal of Neurology published by John Wiley &amp;amp; Sons Ltd on behalf of European Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rakusa</LastName><ForeName>Martin</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-4433-3985</Identifier><AffiliationInfo><Affiliation>Department of Neurologic Diseases, Maribor University Medical Center, Maribor, Slovenia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>&#xd6;zt&#xfc;rk</LastName><ForeName>Serefnur</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurointensive Care, Selcuk University Faculty of Medicine, Konya, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moro</LastName><ForeName>Elena</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-7968-5908</Identifier><AffiliationInfo><Affiliation>Division of Neurology, University Hospital Center of Grenoble, Grenoble Institute of Neurosciences, Grenoble Alpes University, Grenoble, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Helbok</LastName><ForeName>Raimund</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-5682-0145</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bassetti</LastName><ForeName>Claudio L</ForeName><Initials>CL</Initials><Identifier Source="ORCID">0000-0002-4535-0245</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beghi</LastName><ForeName>Ettore</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-2542-0469</Identifier><AffiliationInfo><Affiliation>Mario Negri Institute of Pharmacological Research, Scientific Institute for Research and Health Care, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bereczki</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-8374-0500</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Semmelweis University, Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bodini</LastName><ForeName>Benedetta</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0001-8010-1220</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Saint Antoine Hospital, Public Hospital Network of Paris, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Paris Brain Institute, Sorbonne University, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Liberto</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, Vaudois University Hospital Center and University of Lausanne, Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jenkins</LastName><ForeName>Thomas M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sheffield Teaching Hospitals National Health Service Foundation Trust, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Macerollo</LastName><ForeName>Antonella</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Walton Centre National Health Service Foundation Trust for Neurology and Neurosurgery, Liverpool, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Systems, Molecular, and Integrative Biology, University of Liverpool, Liverpool, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maia</LastName><ForeName>Luis F</ForeName><Initials>LF</Initials><AffiliationInfo><Affiliation>Department of Neurology, Saint Antonio Hospital, Porto University Hospital Center, Porto, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Research and Innovation in Health, University of Porto, Porto, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martinelli-Boneschi</LastName><ForeName>Filippo</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Neurology Unit and Multiple Sclerosis Center, Ca' Granda Ospedale Maggiore Hospital Polyclinic, Scientific Institute for Research and Health Care Foundation, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathophysiology and Transplantation, Dino Ferrari Center, Neuroscience Section, University of Milan, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pisani</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mondino Foundation, Scientific Institute for Research and Health Care, Pavia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Priori</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-1549-3851</Identifier><AffiliationInfo><Affiliation>Division of Neurology, Department of Neurology, Aldo Ravelli Research Center, University of Milan and ASST Saints Paul and Charles, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sauerbier</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Faculty of Medicine and Cologne University Hospital, University of Cologne, Cologne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soffietti</LastName><ForeName>Riccardo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of Neuro-Oncology, Department of Neuroscience, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taba</LastName><ForeName>Pille</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-5439-1022</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Neurosurgery, Institute of Clinical Medicine, Tartu, Estonia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tartu University Hospital, Tartu, Estonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>von Oertzen</LastName><ForeName>Tim J</ForeName><Initials>TJ</Initials><Identifier Source="ORCID">0000-0003-2164-7842</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Neuromed Campus, Kepler University Hospital, Linz, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Faculty, Johannes Kepler University, Linz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zedde</LastName><ForeName>Marialuisa</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-7530-818X</Identifier><AffiliationInfo><Affiliation>Neurology Unit, Neuromotor and Rehabilitation Department, USL-IRCCS Company of Reggio Emilia, Reggio Emilia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crean</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>European Academy of Neurology Head Office, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burlica</LastName><ForeName>Anja</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>European Academy of Neurology Head Office, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cavallieri</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Neurology Unit, Neuromotor and Rehabilitation Department, USL-IRCCS Company of Reggio Emilia, Reggio Emilia, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sellner</LastName><ForeName>Johann</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-8749-5533</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Mistelbach-G&#xe4;nserndorf State Hospital, Mistelbach, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>European Academy of&#xa0;Neurology NeuroCOVID-19 Task&#xa0;Force</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>05</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Neurol</MedlineTA><NlmUniqueID>9506311</NlmUniqueID><ISSNLinking>1351-5101</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009422" MajorTopicYN="Y">Nervous System Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000088823" MajorTopicYN="Y">Vaccination Hesitancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">advocacy</Keyword><Keyword MajorTopicYN="N">infectious disease prevention</Keyword><Keyword MajorTopicYN="N">neurological disorders</Keyword><Keyword MajorTopicYN="N">vaccination</Keyword><Keyword MajorTopicYN="N">vaccine skepticism</Keyword></KeywordList><CoiStatement>E.M. reports personal fees from sources outside the submitted work. The other authors have no conflict of interest to report.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>4</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>4</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>23</Day><Hour>8</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>5</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35460319</ArticleId><ArticleId IdType="pmc">PMC9111566</ArticleId><ArticleId IdType="doi">10.1111/ene.15368</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sellner J, Jenkins TM, von Oertzen TJ, et al. Primary prevention of COVID&#x2010;19: advocacy for vaccination from a neurological perspective. Eur J Neurol. 2021;28(10):3226&#x2010;3229.</Citation><ArticleIdList><ArticleId IdType="pubmed">33386655</ArticleId></ArticleIdList></Reference><Reference><Citation>Leidner AJ, Murthy N, Chesson HW, et al. Cost&#x2010;effectiveness of adult vaccinations: a systematic review. Vaccine. 2019;37(2):226&#x2010;234.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6545890</ArticleId><ArticleId IdType="pubmed">30527660</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddy KP, Fitzmaurice KP, Scott JA, et al. Clinical outcomes and cost&#x2010;effectiveness of COVID&#x2010;19 vaccination in South Africa. Nat Commun. 2021;12(1):6238.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8556310</ArticleId><ArticleId IdType="pubmed">34716349</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin DY, Gu Y, Wheeler B, et al. Effectiveness of covid&#x2010;19 vaccines over a 9&#x2010;month period in North Carolina. N Engl J Med. 2022;386(10):933&#x2010;941.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8781317</ArticleId><ArticleId IdType="pubmed">35020982</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreira ED Jr, Kitchin N, Xu X, et al. Safety and efficacy of a third dose of BNT162b2 covid&#x2010;19 vaccine. N Engl J Med. 2022;386(20):1910&#x2010;1921. doi:10.1056/NEJMoa2200674</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2200674</ArticleId><ArticleId IdType="pmc">PMC9006787</ArticleId><ArticleId IdType="pubmed">35320659</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonelli M, Penfold RS, Merino J, et al. Risk factors and disease profile of post&#x2010;vaccination SARS&#x2010;CoV&#x2010;2 infection in UK users of the COVID Symptom Study app: a prospective, community&#x2010;based, nested, case&#x2010;control study. Lancet Infect Dis. 2022;22(1):43&#x2010;55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8409907</ArticleId><ArticleId IdType="pubmed">34480857</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuodi P, Gorelik Y, Zayyad H, et al. Association between vaccination status and reported incidence of post&#x2010;acute COVID&#x2010;19 symptoms in Israel: a cross&#x2010;sectional study of patients tested between March 2020 and November 2021. medRxiv. 2022:2022.01.05.22268800.</Citation></Reference><Reference><Citation>Schaffer DeRoo S, Pudalov NJ, Fu LY. Planning for a COVID&#x2010;19 vaccination program. JAMA. 2020;323(24):2458&#x2010;2459.</Citation><ArticleIdList><ArticleId IdType="pubmed">32421155</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldman E. How the unvaccinated threaten the vaccinated for COVID&#x2010;19: a Darwinian perspective. Proc Natl Acad Sci USA. 2021;118(39):e2114279118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8488691</ArticleId><ArticleId IdType="pubmed">34544881</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinceti SR. COVID&#x2010;19 compulsory vaccination and the European Court of Human Rights. Acta Biomed. 2021;92(S6):e2021472.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8851021</ArticleId><ArticleId IdType="pubmed">34739454</ArticleId></ArticleIdList></Reference><Reference><Citation>King J, Ferraz OLM, Jones A. Mandatory COVID&#x2010;19 vaccination and human rights. Lancet. 2021;399(10321):220&#x2010;222.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8700276</ArticleId><ArticleId IdType="pubmed">34953527</ArticleId></ArticleIdList></Reference><Reference><Citation>Helbok R, Chou SH, Beghi E, et al. NeuroCOVID: it's time to join forces globally. Lancet Neurol. 2020;19(10):805&#x2010;806.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7494307</ArticleId><ArticleId IdType="pubmed">32949535</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao Y, Chen Y, Liu M, et al. Nervous system diseases are associated with the severity and mortality of patients with COVID&#x2010;19: a systematic review and meta&#x2010;analysis. Epidemiol Infect. 2021;149:e66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7985867</ArticleId><ArticleId IdType="pubmed">33583450</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia&#x2010;Azorin D, Martinez&#x2010;Pias E, Trigo J, et al. Neurological comorbidity is a predictor of death in covid&#x2010;19 disease: a cohort study on 576 patients. Front Neurol. 2020;11:781.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7358573</ArticleId><ArticleId IdType="pubmed">32733373</ArticleId></ArticleIdList></Reference><Reference><Citation>Romagnolo A, Balestrino R, Imbalzano G, et al. Neurological comorbidity and severity of COVID&#x2010;19. J Neurol. 2021;268(3):762&#x2010;769.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7400751</ArticleId><ArticleId IdType="pubmed">32749601</ArticleId></ArticleIdList></Reference><Reference><Citation>Siahaan YMT, Ketaren RJ, Hartoyo V, Hariyanto TI. Epilepsy and the risk of severe coronavirus disease 2019 outcomes: a systematic review, meta&#x2010;analysis, and meta&#x2010;regression. Epilepsy Behav. 2021;125:108437.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8590948</ArticleId><ArticleId IdType="pubmed">34839246</ArticleId></ArticleIdList></Reference><Reference><Citation>Jakubikova M, Tyblova M, Tesar A, et al. Predictive factors for a severe course of COVID&#x2010;19 infection in myasthenia gravis patients with an overall impact on myasthenic outcome status and survival. Eur J Neurol. 2021;28(10):3418&#x2010;3425.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8239548</ArticleId><ArticleId IdType="pubmed">34080271</ArticleId></ArticleIdList></Reference><Reference><Citation>Hariyanto TI, Putri C, Arisa J, Situmeang RFV, Kurniawan A. Dementia and outcomes from coronavirus disease 2019 (COVID&#x2010;19) pneumonia: a systematic review and meta&#x2010;analysis. Arch Gerontol Geriatr. 2021;93:104299.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7674980</ArticleId><ArticleId IdType="pubmed">33285424</ArticleId></ArticleIdList></Reference><Reference><Citation>Prosperini L, Tortorella C, Haggiag S, Ruggieri S, Galgani S, Gasperini C. Determinants of COVID&#x2010;19&#x2010;related lethality in multiple sclerosis: a meta&#x2010;regression of observational studies. J Neurol. 2022;269:2275&#x2010;2285.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8726522</ArticleId><ArticleId IdType="pubmed">34984514</ArticleId></ArticleIdList></Reference><Reference><Citation>Etemadifar M, Nouri H, Maracy MR, et al. Risk factors of severe COVID&#x2010;19 in people with multiple sclerosis: a systematic review and meta&#x2010;analysis. Rev Neurol (Paris). 2021;178(1&#x2010;2):121&#x2010;128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8566345</ArticleId><ArticleId IdType="pubmed">34836608</ArticleId></ArticleIdList></Reference><Reference><Citation>Sellner J, Rommer PS. Multiple sclerosis and SARS&#x2010;CoV&#x2010;2 vaccination: considerations for immune&#x2010;depleting therapies. Vaccines (Basel). 2021;9(2):99.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7911298</ArticleId><ArticleId IdType="pubmed">33525459</ArticleId></ArticleIdList></Reference><Reference><Citation>Garjani A, Middleton RM, Hunter R, et al. COVID&#x2010;19 is associated with new symptoms of multiple sclerosis that are prevented by disease modifying therapies. Mult Scler Relat Disord. 2021;52:102939.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9585399</ArticleId><ArticleId IdType="pubmed">34010764</ArticleId></ArticleIdList></Reference><Reference><Citation>Sellner J, Jenkins TM, von Oertzen TJ, et al. A plea for equitable global access to COVID&#x2010;19 diagnostics, vaccination and therapy: the NeuroCOVID&#x2010;19 Task Force of the European Academy of Neurology. Eur J Neurol. 2021;28(11):3849&#x2010;3855.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8014664</ArticleId><ArticleId IdType="pubmed">33460486</ArticleId></ArticleIdList></Reference><Reference><Citation>Russo AG, Decarli A, Valsecchi MG. Strategy to identify priority groups for COVID&#x2010;19 vaccination: a population based cohort study. Vaccine. 2021;39(18):2517&#x2010;2525.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7997303</ArticleId><ArticleId IdType="pubmed">33824037</ArticleId></ArticleIdList></Reference><Reference><Citation>Machingaidze S, Wiysonge CS. Understanding COVID&#x2010;19 vaccine hesitancy. Nat Med. 2021;27(8):1338&#x2010;1339.</Citation><ArticleIdList><ArticleId IdType="pubmed">34272500</ArticleId></ArticleIdList></Reference><Reference><Citation>Trogen B, Pirofski LA. Understanding vaccine hesitancy in COVID&#x2010;19. Med (N Y). 2021;2(5):498&#x2010;501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8030992</ArticleId><ArticleId IdType="pubmed">33851144</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler R, MacDonald NE, Hesitancy SWGoV . Diagnosing the determinants of vaccine hesitancy in specific subgroups: the guide to tailoring immunization programmes (TIP). Vaccine. 2015;33(34):4176&#x2010;4179.</Citation><ArticleIdList><ArticleId IdType="pubmed">25896376</ArticleId></ArticleIdList></Reference><Reference><Citation>Razai MS, Chaudhry UAR, Doerholt K, Bauld L, Majeed A. Covid&#x2010;19 vaccination hesitancy. BMJ. 2021;373:n1138.</Citation><ArticleIdList><ArticleId IdType="pubmed">34016653</ArticleId></ArticleIdList></Reference><Reference><Citation>Muric G, Wu Y, Ferrara E. COVID&#x2010;19 vaccine hesitancy on social media: building a public twitter data set of antivaccine content, vaccine misinformation, and conspiracies. JMIR Public Health Surveill. 2021;7(11):e30642.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8694238</ArticleId><ArticleId IdType="pubmed">34653016</ArticleId></ArticleIdList></Reference><Reference><Citation>Fasano A, Daniele A. Functional disorders after COVID&#x2010;19 vaccine fuel vaccination hesitancy. J Neurol Neurosurg Psychiatry. 2021;93(3):339&#x2010;340.</Citation><ArticleIdList><ArticleId IdType="pubmed">34408004</ArticleId></ArticleIdList></Reference><Reference><Citation>Linden SC, Carson AJ, Wessely S. Functional neurological disorder after vaccination: a balanced approach informed by history. J R Coll Physicians Edinb. 2021;51(4):330&#x2010;331.</Citation><ArticleIdList><ArticleId IdType="pubmed">34882128</ArticleId></ArticleIdList></Reference><Reference><Citation>Team WP . Causality assessment of an adverse event following immunization (AEFI): user manual for the revised WHO classification, 2nd ed. Organisation WH, editor. WHO; 2021. 16 April 2021.</Citation></Reference><Reference><Citation>Garg RK, Paliwal VK. Spectrum of neurological complications following COVID&#x2010;19 vaccination. Neurol Sci. 2021;43(1):3&#x2010;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8557950</ArticleId><ArticleId IdType="pubmed">34719776</ArticleId></ArticleIdList></Reference><Reference><Citation>Patone M, Handunnetthi L, Saatci D, et al. Neurological complications after first dose of COVID&#x2010;19 vaccines and SARS&#x2010;CoV&#x2010;2 infection. Nat Med. 2021;27(12):2144&#x2010;2153.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8629105</ArticleId><ArticleId IdType="pubmed">34697502</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaulen LD, Doubrovinskaia S, Mooshage C, et al. Neurological autoimmune diseases following vaccinations against SARS&#x2010;CoV&#x2010;2: a case series. Eur J Neurol. 2021;29(2):555&#x2010;563.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8652629</ArticleId><ArticleId IdType="pubmed">34668274</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferro JM, de Sousa DA, Coutinho JM, Martinelli I. European stroke organization interim expert opinion on cerebral venous thrombosis occurring after SARS&#x2010;CoV&#x2010;2 vaccination. Eur Stroke J. 2021;6(3):CXVI&#x2010;CXXI.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8564159</ArticleId><ArticleId IdType="pubmed">34746428</ArticleId></ArticleIdList></Reference><Reference><Citation>Lippi G, Favaloro EJ. Cerebral venous thrombosis developing after COVID&#x2010;19 vaccination: VITT, VATT, TTS, and more. Semin Thromb Hemost. 2022;48(1):8&#x2010;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">34695859</ArticleId></ArticleIdList></Reference><Reference><Citation>Greinacher A, Selleng K, Palankar R, et al. Insights in ChAdOx1 nCoV&#x2010;19 vaccine&#x2010;induced immune thrombotic thrombocytopenia. Blood. 2021;138(22):2256&#x2010;2268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8483989</ArticleId><ArticleId IdType="pubmed">34587242</ArticleId></ArticleIdList></Reference><Reference><Citation>Yap SM, Al Hinai M, Gaughan M, et al. Vaccine hesitancy among people with multiple sclerosis. Mult Scler Relat Disord. 2021;56:103236.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8411656</ArticleId><ArticleId IdType="pubmed">34507240</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu L, Zhang Q, Xiao J, et al. COVID&#x2010;19 vaccine take&#x2010;up rate and safety in adults with epilepsy: data from a multicenter study in China. Epilepsia. 2021;63(1):244&#x2010;251.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9011689</ArticleId><ArticleId IdType="pubmed">34806164</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiao S, Zhang RR, Yang TT, et al. Attitudes to being vaccinated against COVID&#x2010;19: a survey of people with epilepsy in China. Front Neurol. 2021;12:743110.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8523890</ArticleId><ArticleId IdType="pubmed">34675874</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehde DM, Roberts MK, Humbert AT, Herring TE, Alschuler KN. COVID&#x2010;19 vaccine hesitancy in adults with multiple sclerosis in the United States: a follow up survey during the initial vaccine rollout in 2021. Mult Scler Relat Disord. 2021;54:103163.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8295053</ArticleId><ArticleId IdType="pubmed">34325399</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulte EC, Sellner J. SARS&#x2010;CoV&#x2010;2 vaccination in multiple sclerosis: a clearer picture for the time point during CD20 depleting therapy. EBioMedicine. 2021;73:103635.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8515038</ArticleId><ArticleId IdType="pubmed">34656879</ArticleId></ArticleIdList></Reference><Reference><Citation>Bsteh G, Sellner J. T cells as the hoped&#x2010;for savior for SARS&#x2010;CoV&#x2010;2 vaccination during CD20&#x2010;depleting antibody therapy?: commentary for: "Discordant humoral and T cell immune responses to SARS&#x2010;CoV&#x2010;2 vaccination in people with multiple sclerosis on anti&#x2010;CD20 therapy". EBioMedicine. 2021;74:103692.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8579751</ArticleId><ArticleId IdType="pubmed">34773893</ArticleId></ArticleIdList></Reference><Reference><Citation>Achtnichts L, Jakopp B, Oberle M, et al. Humoral immune response after the third SARS&#x2010;CoV&#x2010;2 mRNA vaccination in CD20 depleted people with multiple sclerosis. Vaccines (Basel). 2021;9(12):1470.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8707582</ArticleId><ArticleId IdType="pubmed">34960216</ArticleId></ArticleIdList></Reference><Reference><Citation>Phanhdone T, Drummond P, Meisel T, et al. Barriers to vaccination among people with Parkinson's disease and implications for COVID&#x2010;19. J Parkinsons Dis. 2021;11(3):1057&#x2010;1065.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8355058</ArticleId><ArticleId IdType="pubmed">33935103</ArticleId></ArticleIdList></Reference><Reference><Citation>Bloem BR, Trenkwalder C, Sanchez&#x2010;Ferro A, et al. COVID&#x2010;19 vaccination for persons with Parkinson's disease: light at the end of the tunnel? J Parkinsons Dis. 2021;11(1):3&#x2010;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7990445</ArticleId><ArticleId IdType="pubmed">33523021</ArticleId></ArticleIdList></Reference><Reference><Citation>Li N, Chu C, Lin W. A survey of hesitancy and response to the COVID&#x2010;19 vaccine among patients with epilepsy in Northeast China. Front Neurol. 2021;12:778618.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8635519</ArticleId><ArticleId IdType="pubmed">34867767</ArticleId></ArticleIdList></Reference><Reference><Citation>Puteikis K, Mameniskiene R. Factors associated with COVID&#x2010;19 vaccine hesitancy among people with epilepsy in Lithuania. Int J Environ Res Public Health. 2021;18(8):4374.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8074300</ArticleId><ArticleId IdType="pubmed">33924140</ArticleId></ArticleIdList></Reference><Reference><Citation>Monschein T, Hartung HP, Zrzavy T, et al. Vaccination and multiple sclerosis in the era of the COVID&#x2010;19 pandemic. J Neurol Neurosurg Psychiatry. 2021;92(10):1033&#x2010;1043.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8458056</ArticleId><ArticleId IdType="pubmed">34353858</ArticleId></ArticleIdList></Reference><Reference><Citation>Nistri R, Barbuti E, Rinaldi V, et al. Case report: multiple sclerosis relapses after vaccination against SARS&#x2010;CoV2: a series of clinical cases. Front Neurol. 2021;12:765954.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8569136</ArticleId><ArticleId IdType="pubmed">34744992</ArticleId></ArticleIdList></Reference><Reference><Citation>Pignolo A, Aprile M, Gagliardo C, et al. Clinical onset and multiple sclerosis relapse after SARS&#x2010;CoV&#x2010;2 infection. Neurol Int. 2021;13(4):695&#x2010;700.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8707620</ArticleId><ArticleId IdType="pubmed">34940752</ArticleId></ArticleIdList></Reference><Reference><Citation>Maniscalco GT, Manzo V, Di Battista ME, et al. Severe multiple sclerosis relapse after COVID&#x2010;19 vaccination: a case report. Front Neurol. 2021;12:721502.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8382847</ArticleId><ArticleId IdType="pubmed">34447349</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Filippo M, Cordioli C, Malucchi S, et al. mRNA COVID&#x2010;19 vaccines do not increase the short&#x2010;term risk of clinical relapses in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2021;93(4):448&#x2010;450.</Citation><ArticleIdList><ArticleId IdType="pubmed">34408003</ArticleId></ArticleIdList></Reference><Reference><Citation>Achiron A, Dolev M, Menascu S, et al. COVID&#x2010;19 vaccination in patients with multiple sclerosis: what we have learnt by February 2021. Mult Scler. 2021;27(6):864&#x2010;870.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8114441</ArticleId><ArticleId IdType="pubmed">33856242</ArticleId></ArticleIdList></Reference><Reference><Citation>Ismail II, Salama S. A systematic review of cases of CNS demyelination following COVID&#x2010;19 vaccination. J Neuroimmunol. 2021;362:577765.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8577051</ArticleId><ArticleId IdType="pubmed">34839149</ArticleId></ArticleIdList></Reference><Reference><Citation>Lahoz Fernandez PE, Miranda Pereira J, Fonseca Risso I, et al. Guillain&#x2010;Barre syndrome following COVID&#x2010;19 vaccines: a scoping review. Acta Neurol Scand. 2021;145(4):393&#x2010;398.</Citation><ArticleIdList><ArticleId IdType="pubmed">34967005</ArticleId></ArticleIdList></Reference><Reference><Citation>Epstein S, Xia Z, Lee AJ, et al. Vaccination against SARS&#x2010;CoV&#x2010;2 in neuroinflammatory disease: early safety/tolerability data. Mult Scler Relat Disord. 2021;57:103433.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8638239</ArticleId><ArticleId IdType="pubmed">34923427</ArticleId></ArticleIdList></Reference><Reference><Citation>Serrazina F, Sobral Pinho A, Cabral G, Salavisa M, Correia AS. Willingness to be vaccinated against COVID&#x2010;19: an exploratory online survey in a Portuguese cohort of multiple sclerosis patients. Mult Scler Relat Disord. 2021;51:102880.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7932878</ArticleId><ArticleId IdType="pubmed">33740481</ArticleId></ArticleIdList></Reference><Reference><Citation>Napolitano D, Privitera G, Schiavoni E, et al. The educational role of IBD nurses in Italy in vaccinations: do not miss the moment for COVID&#x2010;19. Eur Rev Med Pharmacol Sci. 2021;25(17):5542&#x2010;5546.</Citation><ArticleIdList><ArticleId IdType="pubmed">34533804</ArticleId></ArticleIdList></Reference><Reference><Citation>Okuhara T, Ishikawa H, Ueno H, Okada H, Kato M, Kiuchi T. Readability assessment of vaccine information: a systematic review for addressing vaccine hesitancy. Patient Educ Couns. 2021;105(2):331&#x2010;338.</Citation><ArticleIdList><ArticleId IdType="pubmed">34090717</ArticleId></ArticleIdList></Reference><Reference><Citation>Meo SA, Meo AS, Al&#x2010;Jassir FF, Klonoff DC. Omicron SARS&#x2010;CoV&#x2010;2 new variant: global prevalence and biological and clinical characteristics. Eur Rev Med Pharmacol Sci. 2021;25(24):8012&#x2010;8018.</Citation><ArticleIdList><ArticleId IdType="pubmed">34982465</ArticleId></ArticleIdList></Reference><Reference><Citation>von Oertzen TJ, Macerollo A, Leone MA, et al. EAN consensus statement for management of patients with neurological diseases during the COVID&#x2010;19 pandemic. Eur J Neurol. 2021;28(1):7&#x2010;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7675361</ArticleId><ArticleId IdType="pubmed">33058321</ArticleId></ArticleIdList></Reference><Reference><Citation>Moro E, Priori A, Beghi E, et al. The international European Academy of Neurology survey on neurological symptoms in patients with COVID&#x2010;19 infection. Eur J Neurol. 2020;27(9):1727&#x2010;1737.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7323212</ArticleId><ArticleId IdType="pubmed">32558002</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>